Results 11 to 20 of about 797 (159)

A combinatorial CAAR-T cell strategy to eliminate factor VIII inhibitors in preclinical models of hemophilia A [PDF]

iScience
Summary: Chimeric autoantibody receptor T (CAAR-T) cell therapy extends CAR-T technology to target autoreactive immune cells, offering a novel approach for treating autoimmune disorders.
Wenjie Li, Qirui Yang, Shuping Lai, Rongfang Wei, Lisheng Cai, Xue Zhang, Xin He, Yan Chen   +7 more
doaj   +2 more sources

Chimeric autoantibody receptor T cells for targeted depletion of myeloperoxidase-specific anti-neutrophil cytoplasmic antibody-producing B cells [PDF]

Frontiers in Immunology
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitides are autoimmune disorders driven by autoantibodies against neutrophil granule proteins, myeloperoxidase (MPO) and proteinase 3, which cause necrotizing small-vessel inflammation with prominent lung ...
Heather M. Sosnoski, William Aguilar, Shawna K. Brookens, David A. Degaramo, John T. Keane, Hyeon-Gyu S. Lewis, Damodar Gullipalli, Wenchao Song, Avery D. Posey, Avery D. Posey   +9 more
doaj   +2 more sources

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy [PDF]

Frontiers in Immunology
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of selected hematologic malignancies, particularly relapsed or refractory large B-cell lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. However, currently
Tomasz Buczek, Tomasz Buczek, Aleksandra Butrym, Aleksandra Butrym   +3 more
doaj   +2 more sources

Chimeric autoantibody receptor T cells specifically eliminate Graves’ Disease autoreactive B cells [PDF]

Frontiers in Immunology
IntroductionChimeric antigen receptor (CAR) T cells have recently become an important treatment for hematological cancers by efficiently eliminating B cells.
Abigail Cheever, Hunter G. Lindsay, Chloe C. Kang, Mackenzie Hansen, Kimball Demars, Kim L. O’Neill, K. Scott Weber   +6 more
doaj   +2 more sources

Chimeric Antigen Receptor T-Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions. [PDF]

Muscle Nerve
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Hegelmaier T, Duscha A, Desel C, Stassen S, Krzemien T, Hennemann AK, Pappa V, Haghikia A.   +7 more
europepmc   +2 more sources

Calcium-mediated actin reset (CaAR) mediates acute cell adaptations

eLife, 2016
Actin has well established functions in cellular morphogenesis. However, it is not well understood how the various actin assemblies in a cell are kept in a dynamic equilibrium, in particular when cells have to respond to acute signals.
Pauline Wales, Christian E Schuberth, Roland Aufschnaiter, Johannes Fels, Ireth García-Aguilar, Annette Janning, Christopher P Dlugos, Marco Schäfer-Herte, Christoph Klingner, Mike Wälte, Julian Kuhlmann, Ekaterina Menis, Laura Hockaday Kang, Kerstin C Maier, Wenya Hou, Antonella Russo, Henry N Higgs, Hermann Pavenstädt, Thomas Vogl, Johannes Roth, Britta Qualmann, Michael M Kessels, Dietmar E Martin, Bela Mulder, Roland Wedlich-Söldner   +24 more
doaj   +5 more sources

Association of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios With Three-Vessel Coronary Artery Disease: A Case-Control Study. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Coronary artery disease (CAD) is a leading cause of mortality worldwide, with inflammation playing a crucial role in its pathogenesis. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are emerging as potential inflammatory biomarkers for CAD severity. This study investigates the association of
Ayazkhoo L, Sistanizad M, Haji Aghajani M, Sadeghi R, Jafari Z, Taherpour N.   +5 more
europepmc   +2 more sources

Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]

HLA
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, Roelen DL, Heemskerk MHM, Heidt S.   +8 more
europepmc   +2 more sources

Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies [PDF]

Frontiers in Immunology
With the expanding identification of target antigens in primary membranous nephropathy (PMN), treatment is shifting from empirical immunosuppression toward mechanism-based precision immunotherapy.
Jingjie Gao, Jingjie Gao, Yanan Pei, Yanan Pei, Lijuan Wei, Lijuan Wei, Bo Yang, Bo Yang, Hongtao Yang, Hongtao Yang   +9 more
doaj   +2 more sources

GPIbα CAAR-T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia [PDF]

Haematologica
Breakthrough treatment for refractory and relapsed immune thrombocytopenia (ITP) patients is urgently needed. Autoantibody-mediated platelet clearance and megakaryocyte dysfunction are important pathogenic mediators of ITP.
Jie Zhou, Yanyan Xu, Jinhui Shu, Haojie Jiang, Linlin Huang, Min Xu, Junling Liu, Yu Hu, Heng Mei   +8 more
doaj   +2 more sources